Alexandra Bazeos

1.7k total citations · 1 hit paper
16 papers, 1.0k citations indexed

About

Alexandra Bazeos is a scholar working on Genetics, Pathology and Forensic Medicine and Oncology. According to data from OpenAlex, Alexandra Bazeos has authored 16 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Genetics, 8 papers in Pathology and Forensic Medicine and 4 papers in Oncology. Recurrent topics in Alexandra Bazeos's work include Chronic Lymphocytic Leukemia Research (8 papers), Lymphoma Diagnosis and Treatment (8 papers) and Chronic Myeloid Leukemia Treatments (4 papers). Alexandra Bazeos is often cited by papers focused on Chronic Lymphocytic Leukemia Research (8 papers), Lymphoma Diagnosis and Treatment (8 papers) and Chronic Myeloid Leukemia Treatments (4 papers). Alexandra Bazeos collaborates with scholars based in United Kingdom, Switzerland and United States. Alexandra Bazeos's co-authors include Dragana Milojković, Richard Szydlo, Letizia Foroni, Jane F. Apperley, Jamshid S. Khorashad, David Marín, Christos Paliompeis, Lina Eliasson, Alistair Reid and Mathiéu Molimard and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Clinical Cancer Research.

In The Last Decade

Alexandra Bazeos

16 papers receiving 1.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Adherence Is the Critical Factor for Achieving Molecular Responses in Patients With Chronic Myeloid Leukemia Who Achieve Complete Cytogenetic Responses on Imatinib

2010 674 citations David Marín, Alexandra Bazeos et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Alexandra Bazeos

Since Specialization

Citations

This map shows the geographic impact of Alexandra Bazeos's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alexandra Bazeos with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alexandra Bazeos more than expected).

Fields of papers citing papers by Alexandra Bazeos

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alexandra Bazeos. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alexandra Bazeos. The network helps show where Alexandra Bazeos may publish in the future.

Co-authorship network of co-authors of Alexandra Bazeos

This figure shows the co-authorship network connecting the top 25 collaborators of Alexandra Bazeos. A scholar is included among the top collaborators of Alexandra Bazeos based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alexandra Bazeos. Alexandra Bazeos is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

#	Work	Indexed citations
1	Glofitamab Induces High Response Rates and Durable Remissions in Patients (Pts) with Heavily Pretreated Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL), Including Those with a Poor Prognosis: Subgroup Results from a Phase I/II Study 2024 ·Blood ·Tycel Phillips, Marek Trněný, Carmelo Carlo‐Stella, Jan Maciej Zaucha, Tomasz Wróbel, Fritz Offner, Michael Dickinson, Monica Tani, Michael Crump, Nancy L. Bartlett, Joaquín Martínez‐López, Paolo Corradini, (unknown), Alessia Bottos, Derrick Kaufman, James Relf, (unknown), Alexandra Bazeos, Linda Lundberg, Franck Morschhauser	2
2	Glofitamab (Glofit) Plus R-CHOP Has a Favorable Safety Profile and Induces High Response Rates in Patients with Previously Untreated (1L) Large B-Cell Lymphoma (LBCL) Defined As High Risk By Circulating Tumor DNA (ctDNA) Dynamics: Preliminary Safety and Efficacy Results 2023 ·Blood ·Lorenzo Falchi, Fabrice Jardin, Corinne Haïoun, Tomasz Wróbel, (unknown), Mariana Bastos‐Oreiro, Eric Mou, Joaquín Martínez‐López, Lihua E. Budde, Nancy L. Bartlett, Jan Maciej Zaucha, Alejandro Martı́n, (unknown), (unknown), Ron McCord, Alexandra Bazeos, Maneesh Tandon, Michelle Y. Doral, (unknown), Marcel Nijland	14
3	Prognostic mutational subtyping in de novo diffuse large B-cell lymphoma 2022 ·BMC Cancer ·Eugene Kim, Yanwen Jiang, (unknown), Alexandra Bazeos, Andrea Knapp, Christopher R. Bolen, Kathryn Humphrey, Tina Nielsen, Elicia Penuel, Joseph N. Paulson	5
4	Population Pharmacokinetics and Exposure–Response Analyses for Venetoclax in Combination with R-CHOP in Relapsed/Refractory and Previously Untreated Patients with Diffuse Large B Cell Lymphoma 2021 ·Advances in Therapy ·Divya Samineni, Weize Huang, Leonid Gibiansky, Hao Ding, (unknown), Chunze Li, Arijit Sinha, (unknown), Kathryn Humphrey, Alexandra Bazeos, Ahmed Hamed Salem, Dale Miles	9
5	Prognostic Impact of Natural Killer Cell Count in Follicular Lymphoma and Diffuse Large B-cell Lymphoma Patients Treated with Immunochemotherapy 2019 ·Clinical Cancer Research ·Magdalena Klánová, Mikkel Z. Oestergaard, Marek Trněný, Wolfgang Hiddemann, Robert Marcus, Laurie H. Sehn, Umberto Vitolo, Alexandra Bazeos, Valentin Goede, Harald Zeuner, Andrea Knapp, Deniz Şahin, (unknown), Christopher R. Bolen, Andrés F. Cardona, Christian Klein, Jeffrey M. Venstrom, Tina Nielsen, Günter Fingerle‐Rowson	54
6	Mode of progression after first line treatment correlates with outcome of chronic lymphocytic leukemia (CLL) 2019 ·American Journal of Hematology ·Othman Al‐Sawaf, Alexandra Bazeos, Sandra Robrecht, Jasmin Bahlo, (unknown), Anna‐Maria Fink, Julia von Tresckow, Paula Cramer, Petra Langerbeins, Nadine Kutsch, Kathryn Humphrey, Günter Fingerle‐Rowson, Stephan Stilgenbauer, Clemens‐Martin Wendtner, Kirsten Fischer, Barbara Eichhorst, Michael Hallek, Valentin Goede	5
7	Somatic variants in epigenetic modifiers can predict failure of response to imatinib but not to second-generation tyrosine kinase inhibitors 2019 ·Haematologica ·Georgios Nteliopoulos, Alexandra Bazeos, Simone Claudiani, Gareth Gerrard, Edward Curry, Richard Szydlo, Mary Alikian, (unknown), Zacharoula Nikolakopoulou, Sandra Loaiza, Jamshid S. Khorashad, Dragana Milojković, Danilo Perrotti, Robert Peter Gale, Letizia Foroni, Jane F. Apperley	36
8	Recapitulation of Prognostic Mutational Subtyping Utilizing F1H in GOYA and CAVALLI and the Potential to Highlight Benefit of Targeted Therapy in De Novo DLBCL 2019 ·Blood ·(unknown), Jinzhen Fan, Christopher R. Bolen, Alexandra Bazeos, Yanwen Jiang, Sandhya Balasubramanian, (unknown), Andrea Knapp, Kathryn Humphrey, Tina Nielsen, Jeffrey M. Venstrom, Genevive Hernandez, Joseph N. Paulson	1
9	Low Peripheral Blood NK Cell Count Is Associated with Worse Clinical Outcome in Patients with Follicular Lymphoma (FL) and Diffuse Large B-Cell Lymphoma (DLBCL) Treated with Immunochemotherapy: Results from the Frontline Phase 3 GALLIUM and GOYA Trials 2017 ·Blood ·Magdalena Klánová, Mikkel Z. Oestergaard, Marek Trněný, Wolfgang Hiddemann, Robert Marcus, Laurie H. Sehn, Umberto Vitolo, Alexandra Bazeos, Valentin Goede, Harald Zeuner, Andrea Knapp, (unknown), (unknown), Christopher R. Bolen, Susan Robson, Jeffrey M. Venstrom, Tina Nielsen, Günter Fingerle‐Rowson	2
10	Evaluation of Fatigue in Previously Untreated CLL Patients with Comorbidities Treated with Obinutuzumab (GA101) + Chlorambucil (GClb) or Rituximab + Chlorambucil (RClb) 2016 ·Blood ·Valentin Goede, Peter C. Trask, (unknown), Marianne Uguen, Alexandra Bazeos, Kirsten Fischer, Michael Hallek	1
11	Somatic Mutations in Epigenetic Modifiers Identified Using Next Generation Sequencing (NGS) in Diagnostic Samples of CML-CP Can Predict Poor Outcome on Imatinib Which Is Abrogated By Frontline 2G-TKI Therapy 2016 ·Blood ·Georgios Nteliopoulos, Alexandra Bazeos, Gareth Gerrard, Simone Claudiani, Edward Curry, Mary Alikian, (unknown), Letizia Foroni, Jane F. Apperley	1
12	Buccals are likely to be a more informative surrogate tissue than blood for epigenome-wide association studies 2013 ·Epigenetics ·Robert Lowe, Carolina Gemma, Huriya Beyan, Mohammed I. Hawa, Alexandra Bazeos, Richard David Leslie, Alexandre Montpetit, Vardhman K. Rakyan, Sreeram V. Ramagopalan	125
13	Adherence Is the Critical Factor for Achieving Molecular Responses in Patients With Chronic Myeloid Leukemia Who Achieve Complete Cytogenetic Responses on Imatinib breakdown → 2010 ·Journal of Clinical Oncology ·David Marín, Alexandra Bazeos, François-Xavier Mahon, Lina Eliasson, Dragana Milojković, Marco Bua, Jane F. Apperley, Richard Szydlo, (unknown), Kasia Kozlowski, Christos Paliompeis, Victoria Latham, Letizia Foroni, Mathiéu Molimard, Alistair Reid, Katy Rezvani, Hugues de Lavallade, (unknown), John M. Goldman, Jamshid S. Khorashad	674
14	Application of camera phones in telehaematology 2009 ·Journal of Telemedicine and Telecare ·(unknown), (unknown), Alexandra Bazeos, (unknown)	10
15	BCR-ABL1 Oncogene Down-regulates the Expression of OCT1 in CML. 2009 ·Blood ·Alexandra Bazeos, David Marin, Gareth Gerrard, Richard Szydlo, Dragana Milojković, Alistair Reid, Hugues de Lavallade, Jane F. Apperley, John M. Goldman, Letizia Foroni, Jamshid S. Khorashad	2
16	Are Helicobacter Species and Enterotoxigenic Bacteroides fragilis Involved in Inflammatory Bowel Disease? 2004 ·Digestive Diseases and Sciences ·Christelle Basset, John Holton, Alexandra Bazeos, Dino Vaira, Stuart Bloom	99

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact